Pfizer 2014 Annual Report Download - page 25

Download and view the complete annual report

Please find page 25 of the 2014 Pfizer annual report below. You can navigate through the pages in the report by either clicking on the pages listed below, or by using the keyword search tool below to find specific information within the annual report.

Page out of 75

  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • 38
  • 39
  • 40
  • 41
  • 42
  • 43
  • 44
  • 45
  • 46
  • 47
  • 48
  • 49
  • 50
  • 51
  • 52
  • 53
  • 54
  • 55
  • 56
  • 57
  • 58
  • 59
  • 60
  • 61
  • 62
  • 63
  • 64
  • 65
  • 66
  • 67
  • 68
  • 69
  • 70
  • 71
  • 72
  • 73
  • 74
  • 75

PFIZER ANNUAL REVIEW 2014 www.pzer.com/annual 25
ANNUAL REVIEW 2014
GLOBAL INNOVATIVE PHARMA BUSINESS
Global Innovative Pharma (GIP) is focused on developing,
registering and commercializing novel, value-creating medicines
that signicantly improve patients’ lives. These therapeutic areas
include inammation, cardiovascular/metabolic, neuroscience
and pain, rare diseases and women’s/men’s health and include
leading brands, such as Xeljanz,® Eliquis® and Lyrica® (U.S. and
Japan). GIP has a robust pipeline of medicines in inammation,
cardiovascular / metabolic disease, pain and rare diseases.
GLOBAL ESTABLISHED PHARMA BUSINESS
Global Established Pharma (GEP) is a large and highly diverse
business with unique opportunities across portfolios and
geographies. It is comprised of three primary product segments
with different market dynamics:
• Peri-LOE products in developed markets — these products have
recently lost, or are approaching loss of marketing exclusivity
• Legacy established products in developed markets — comprised of
mature products that have lost marketing exclusivity, and including
growth opportunities in developed markets
• Emerging Markets — comprised of all GEP products sold in
emerging markets, and including growth opportunities.
Growth opportunities are another key area of GEP’s legacy
established products segment, in both developed and emerging
markets. These opportunities are comprised of organic and inorganic
initiatives, such as partnerships, product enhancements, sterile
injectables and biosimilars.
Our Business > How We Are Organized